Age and Liver Transplantation

Zetterman, Rowen K.; Belle, Steven H.; Hoofnagle, Jay H.; Lawlor, Sharon; Wei, Yue; Everhart, James E.; Wiesner, Russell H.; Lake, John R.

doi:10.1097/00007890-199808270-00015

Cited by 138 publications

(37 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,9 This susceptibility to rejection reflects the fact that patients with PLD usually belong to a middle-aged group known to be more prone to rejection. 16 In addition, those patients usually do not have advanced liver failure or malnutrition, other factors that can affect the immune system and the incidence of rejection. Although relatively frequent, all rejection episodes that we encountered quickly responded to steroid treatment or conversion to FK506.…”

Section: Discussionmentioning

confidence: 99%

Liver transplantation for polycystic liver disease

et al. 2001

View full text Add to dashboard Cite

Polycystic liver disease (PLD) may provoke massive hepatomegaly and severe physical and social handicaps. Data on orthotopic liver transplantation (OLT) for PLD are rare and conflicting. Conservative surgery (resection or fenestration) is indicated for large single cysts, but its value for small diffuse cysts is questionable. In addition, conservative surgery is not devoid of morbidity and mortality. OLT offers the prospect of a fully curative treatment, but controversy remains because those patients usually have preserved liver function. Thus, we reviewed our experience with OLT for PLD. Sixteen adult women underwent OLT for small diffuse PLD between 1990 and 1999. Mean age was 45 years (range, 34 to 56 years). Fourteen patients had combined liver and kidney cystic disease, but only 1 patient required combined liver and kidney transplantation, whereas 13 patients underwent OLT alone. Two patients had isolated PLD. Indications for transplantation were massive hepatomegaly causing physical handicaps (n ‫؍‬ 16), social handicaps (n ‫؍‬

show abstract

Section: Discussionmentioning

confidence: 99%

Liver transplantation for polycystic liver disease

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In our study, atherosclerotic disease was present in six patients (5.2%) whose mean age was 54 years. The incidence of this complication increases with the liver transplant patient's age [34]. In our series, 53.4% of the patients were < 55 years, which could explain the low prevalence of cardiovascular events.…”

Section: Cardiovascular Diseasementioning

confidence: 53%

Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation

et al. 2002

View full text Add to dashboard Cite

We assessed the cardiovascular risk factors (CVRFs) in 116 stable liver transplant patients surviving for 5 years or more (median: 102 months). The prevalence of smokers was 29.3%, hypertension 49.1 O h , obesity 22.4%. hypercholesterolemia 34.5%, hypertriglyceridemia 11.2%, and hyperhomocysteinemia 57.8%. Diabetes was found in 21.5% of the patients, being more frequent in patients with hepatitis-C-virus infection (31.8% vs 15.3%; P=0.03). Patients on cyclosporine therapy had a higher prevalence of hypertension, hypercholesterolemia and hyperhomocysteinemia than those treated with tacrolimus. Multivariate analysis showed only an association between cyclosporine therapy and cholesterol concentrations (odds ratio: 1.02; 95% confidence interval (CI): 1 .OO-1.03; P = 0.01). The prevalence of hypertension, diabetes, hypercholesterolemia and hypertriglyceridemia was lower at the time of the study than at 1 and 3 years after transplantation (P < 0.05), probably related to steroid withdrawal. Comparing 87 patients' CVRFs with the general Spanish population, we found that the agegender standardized prevalence ratio was not different: smoking 1.46 (95% CI: 0.88-1.76), obesity 1.16 (95% CT: 0.60-1.44), hypertension 1.55 (95% CI: 0.98-1.81), and hypercholesterolemia 0.64 (95%CI: 0.35-1.90). We conclude that the prevalence of CVRFs in liver transplant patients after 5 years or more is lower that found in the first years after the transplantation, and no different from that found within the Spanish population.

show abstract

“…Einzelne Veröffentlichungen aus großen Transplantationszentren zeigen vergleichbare Ergebnisse für die Häufigkeit periund postoperativer Komplikationen und die Dauer des Krankenhausaufenthaltes für Patienten, die älter als 60 Jahre sind [14]. In vielen Serien großer Transplantationszentren sind zudem die 1-und 2-Jahres-Überlebensraten vergleichbar mit denen jüngerer Patienten [7].…”

Section: Ergebnisse Einzelner Zentrenunclassified

“…Erste Erhebungen zur Lebensqualität nach Lebertransplantation zeigen unter Zuhilfenahme von Patientenfragebögen für die meisten Indizes/Score-Systeme vergleichbare Resultate für junge und alte Patienten [14].…”

Section: Diskussionunclassified

Lebertransplantation bei �lteren Patienten

et al. 2004

View full text Add to dashboard Cite

Since the first liver transplantation (OLT) was performed by Starzl in 1963, this has become the standard therapy for end stage chronic liver disease and acute hepatic failure. It is also the therapy of choice in selected cases of hepatic malignancy. Due to the optimization of intra- and perioperative management, new immunosuppressant drugs and improved organ procurement, the clinical outcome in patient and graft survival has increased continuously. The shortage of donor organs has led to the development of new surgical techniques such as split- and living related transplantation. OLT should also be offered to elderly patients. Careful evaluation and patient selection results in good patient and graft survival after transplantation, which is comparable to that in with younger recipients.

show abstract

Age and Liver Transplantation

Cited by 138 publications

References 12 publications

Liver transplantation for polycystic liver disease

Liver transplantation for polycystic liver disease

Cardiovascular risk factors in 116 patients 5 years or more after liver transplantation

Lebertransplantation bei �lteren Patienten

Contact Info

Product

Resources

About